Latest Conference Articles

Panelists Question Efficacy, Immunogenicity Studies for Biosimilars

Tony Hagen

November 3 2020

Certain biosimilar studies are performed out of an abundance of caution and good marketing sense, although science has leapfrogged the need for these trials, panelists said at the Terrapinn Festival of Biologics Basel 2020.

Safety, Efficacy, and Savings Result From Study of Nonmedical Switching

Tony Hagen

October 26 2020

A study of mandatory switching for patients with rheumatologic conditions led to savings without effect on safety or efficacy.

Samsung Bioepis Presents Real-World Switching Data for Renflexis

Tony Hagen

October 26 2020

A retrospective analysis of data from the US Veterans Affairs Healthcare System database provides positive switching data for infliximab products.

Need for Biosimilar Cooperation Among Hospitals, Infusion Centers, and Payers Is Identified

Skylar Jeremias

October 22 2020

Overcoming biosimilar uptake barriers will take collaboration and policy change by hospitals, infusion clinics, and health plans, presenters said at the Academy of Managed Care Pharmacy Nexus 2020 Virtual conference.

Promising Results in CD, UC for Celltrion Infliximab Biosimilar

Skylar Jeremias

October 12 2020

Celltrion Healthcare reports on progress with higher predose levels of the infliximab biosimilar Remsima in patients with Crohn disease (CD) and ulcerative colitis (UC).

International Presenters Share Tips on Beefing Up Biosimilar Use

Skylar Jeremias

October 9 2020

As the United States continues to struggle to increase biosimilar uptake, presenters at the DIA 2020 Biosimilars Conference offered insight into what other countries have done to encourage biosimilar use.

FDA Reshuffles Priorities to Meet COVID-19 Trial Demand

Tony Hagen

October 7 2020

The FDA has had to rely on triaging to address its most critical priorities during the unfolding coronavirus disease 2019 (COVID-19) pandemic, according to Peter P. Stein, MD.

Meier Explains FTC's Power to Pursue Antitrust Activity

Tony Hagen

September 30 2020

The Federal Trade Commission's powers to bring antitrust actions are circumscribed by public versus private and what is vs isn't "reasonable," Markus H. Meier explained.

FTC's Markus H. Meier Talks About Restraint of Trade in the Biosimilar Marketplace

Tony Hagen

September 28 2020

Some acts by companies in the biologics marketplace may go too far in preventing free market activity, according to Markus H. Meier, acting director for the Federal Trade Commission (FTC) Bureau of Competition.

Patt: Payers Could Save More With Biosimilars

Tony Hagen

September 25 2020

Debra Patt, MD, PhD, MBA, discusses issues affecting biosimilar uptake at the Patient-Centered Oncology Care® 2020 virtual conference.